Loading…
Loading…
GRAL's Q3 earnings should have benefited from rising Galleri test adoption, expanding digital health partnerships and growing clinical evidence of cancer detection.
SUNNYVALE, Calif., Oct. 27, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the UBS Global Healthcare Conference in Palm Beach, FL on Tuesday, Nov. 10 at 11:00 a.m.
The S&P 500 recently sat just 2.5% below its all-time high. Look past the index, though, and the picture gets uglier.
SUNNYVALE, Calif., Oct. 21, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue financial results for the third quarter 2026 following the close of market on Wednesday, Nov. 4, 2026.
GRAIL, Inc. (NASDAQ: GRAL - Get Free Report) CEO Joshua Ofman sold 20,000 shares of the firm's stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $136.85, for a total value of $2,737,000.00. Following the transaction, the chief executive officer owned 342,271 shares in the company, valued at
GRAIL, Inc. (NASDAQ: GRAL - Get Free Report)'s stock price dropped 5.6% on Friday after an insider sold shares in the company. The stock traded as low as $129.03 and last traded at $127.9350. 67,481 shares traded hands during trading, a decline of 93% from the average session volume of 971,234 shares. The stock had previously
Bond yields, oil prices, and inflation rhetoric have teamed up to make it tough for investors heading into earnings season.
For a rare breed of travel enthusiast, the free toiletry pouches are more than a throwaway convenience. They're a trip down memory lane.